Acceleron Pharma Announces Phase 3 Clinical Trial Designs

Biopharmaceutical company Acceleron Pharma Inc. (NASDAQ:XLRN) has announced the phase 3 clinical trial designs for the luspatercept program in myelodysplastic syndromes (“MEDALIST” study) and beta-thalassemia (“BELIEVE” study). Furthermore, the company announced phase 1 preliminary results from the ACE-083 program, and its new IntelliTrap™ drug discovery platform.
According to the press release:

“We are extremely excited to present the plans for Acceleron’s first phase 3 clinical trials, the unprecedented increases in muscle mass demonstrated in the ACE-083 phase 1 clinical trial supporting its advancement into phase 2 trials next year and our new IntelliTrap™ drug discovery platform which is already generating promising new therapeutic candidates such as ACE-2494,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron. “Acceleron is making great strides across its entire pipeline from our late stage phase 3 programs to our highly productive discovery organization and I am proud of the tremendous progress we are making.”
[…] Acceleron announced that the phase 3 MDS trial will be a double-blind, randomized, placebo-controlled study of luspatercept in 210 very low to intermediate risk MDS patients (the “MEDALIST” study). The primary endpoint is the proportion of patients that become red blood cell transfusion independent (= 8 weeks) during the first 24 weeks of the study.

 
Click here to read the full press release.